A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

被引：3

作者：

Pemmaraju, Naveen

Marconi, Giovanni

Todisco, Elisabetta

Montesinos, Pau

Lane, Andrew A.

Sweet, Kendra

Wang, Eunice S.

Deconinck, Eric

Rizzieri, David A.

Walter, Roland B.

Aribi, Ahmed

Lebon, Delphine

Levy, Moshe Y.

Mazzarella, Luca

Martinelli, Giovanni

Gigli, Federica

Erba, Harry P.

Acuna-Cruz, Evelyn

Konopleva, Marina

Kantarjian, Hagop

Sloss, Callum M.

Wang, Jiuzhou

Malcolm, Kara E.

Zweidler-McKay, Patrick A.

DeAngelo, Daniel J.

Daver, Naval

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Ist Seragnoli, Bologna, Italy

[3] European Inst Oncol IRCCS, Div Onco Hematol, Milan, Italy

[4] Hosp Univ & Politecn La Fe, Valencia, Spain

[5] Dana Farber Boston Childrens Canc & Blood Disorde, Dept Med Oncol, Boston, MA USA

[6] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

[7] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[8] Besancon Univ Hosp, Clin Hematol, Besancon, France

[9] Duke Univ Med Ctr, Div Hematol Malignancies & Cellular Therapy, Dept Med, Durham, NC USA

[10] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[11] City Hope Natl Med Ctr, Gehr Family Ctr Leukemia Res, Duarte, CA USA

[12] CHU Amiens, Hematol Dept, Amiens, France

[13] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA

[14] European Inst Oncol, Milan, Italy

[15] Inst Hematol LeA Seragnoli, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[16] European Inst Oncol, Milan, Italy

[17] Duke Univ, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA

[18] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[19] ImmunoGen, Waltham, MA USA

[20] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-146681

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4429

引用

页数：10

共 50 条

[21] Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond
Pemmaraju, Naveen
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2017, 12 (06) : 510 - 512
[22] Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in Pediatric Patients with Tagraxofusp, a CD123-Targeted Therapy
Pemmaraju, Naveen
Cuglievan, Branko
Lasky, Joseph L., III
Kheradpour, Albert
Hijiya, Nobuko
Stein, Anthony S.
Pawlowska, Anna B.
BLOOD, 2021, 138
[23] Real world (RW) study of patients (pts) with relapsed or refractory (RR) blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with tagraxofusp (TAG)
Herling, Marco
Angelucci, Emanuele
Manteigas, David
Zuurman, Michael
Deconinck, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[24] Optimization of the CD123 CAR T-cell scFv for the treatment of patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Fredon, M.
Poussard, M.
Biichle, S.
Anna, F.
Bonnefoy, F.
Bole-Richard, E.
Renosi, F.
Caumartin, J.
Loustau, M.
Adotevi, O.
Saas, P.
Angelot-Delettre, F.
Galaine, J.
Garnache-Ottou, F.
HUMAN GENE THERAPY, 2021, 32 (19-20) : A37 - A37
[25] Tagraxofusp, a CD123-Targeted Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Results of a Landmark Clinical Trial
Pemmaraju, Naveen
Lane, Andrew
Sweet, Kendra
Stein, Anthony
Vasu, Sumithira
Blum, William
Rizzieri, David
Wang, Eunice
Duvic, Madeleine
Brooks, Christopher
Sloan, J. Mark
Rosenblat, Todd
Akilov, Oleg
Mughal, Tariq
Lancet, Jeffrey
Kantarjian, Hagop
Konopleva, Marina
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S209 - S210
[26] Synergistic Anti-Leukemic Activity of PARP Inhibition Combined with IMGN632, an Anti-CD123 Antibody-Drug Conjugate in Acute Myeloid Leukemia Models
Fritz, Claire
Portwood, Scott M.
Adams, Julie
Cronin, Tara
Lutgen-Dunckley, Linda
Martens, Brandon L.
Sloss, Callum M.
Watkins, Krystal
Kovtun, Yelena
Adams, Sharlene
Wang, Eunice S.
BLOOD, 2018, 132
[27] Durable Outcomes and Manageable Safety with Tagraxofusp in a Real-World Study of Patients With Treatment-Naive and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Angelucci, Emanuele
Deconinck, Eric
Zuurman, Michael
Herling, Marco
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S306 - S306
[28] Anti-CD38 Monoclonal Antibody Daratuzumab Improve Responses to Chemotherapy-Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Case Report
Li, Xiaoqing
An, Gang
Du, Xin
Chen, Weihong
BLOOD, 2020, 136
[29] Venetoclax Synergizes with IMGN632, a Novel CD123-Targeting Antibody Conjugated to a DNA Alkylating Payload, By Suppressing DNA Damage Response and Potentiating Apoptosis in Acute Myeloid Leukemia in Vitro Models
Skwarska, Anna
Kuruvilla, Vinitha Mary
Zhang, Qi
Chaudhry, Sovira
Daver, Naval
Watkins, Krystal
Sloss, Callum Mortimer
Zweidler-McKay, Patrick A.
Sampath, Deepa
Konopleva, Marina Y.
BLOOD, 2023, 142
[30] Pediatric Preclinical Testing Consortium Evaluation of the Anti-CD123 Antibody-Drug Conjugate, IMGN632, Against Patient-Derived Xenograft Models of Pediatric Acute Lymphoblastic Leukemia
Lock, Richard B.
Evans, Kathryn
Randall, Joanna
Erickson, Stephen W.
Earley, Eric J.
Neuhauser, Steven
Stearns, Tim
Philip, Vivek
Teicher, Beverly A.
Watkins, Krystal
Sloss, Callum M.
Zweidler-McKay, Patrick A.
Smith, Malcolm A.
BLOOD, 2022, 140 : 8983 - 8984

← 1 2 3 4 5 →